Cooperative Agreement 2451182
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$1.3M
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
San Carlos, CA 94070, USA
Similar Awards
Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...
This $1,008,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Vcreate, Inc., a minority-owned small disadvantaged business, in developing a high-throughput platform to screen millions of T-cell receptors (TCRs) against a large set of cancer-related antigens. The objective is to identify and validate clinically valuable TCRs that could serve as the basis for new immunotherapies against solid tumors....
This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Redpoint Oncology, Inc. aims to develop and validate a novel platform for targeted cancer therapies. The project seeks to create "guided missile-like" cancer treatments that can selectively target and destroy therapy-resistant cancer cells. Key research objectives include designing new payload candidates, testing their anti-cancer efficacy and selectivity,...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 was granted to Absco Therapeutics, Inc. (Abscotx) on April 15, 2025 to develop an image-guided intratumoral delivery system for biologic cancer immunotherapies. The project aims to improve localized retention and controlled release of biologic drugs within solid tumors, addressing limitations of current systemic administration methods that suffer from rapid drug...
Vcreate, Inc. was awarded a $256,000 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a high-throughput platform for discovering T-cell receptor (TCR) based immunotherapies for late-stage cancer patients. The platform aims to screen thousands of TCRs against thousands of cancer antigens to identify clinically relevant TCRs that could serve as the basis for new treatments against currently incurable cancers....
This $274,975 Small Business Innovation Research (SBIR) Phase I grant awarded by the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of an antibody therapy targeting neoantigens in acute myeloid leukemia (AML). The project aims to create a platform technology that combines cancer-specific antibodies and adoptive natural killer (NK) immune cells to achieve high efficacy and low toxicity in treating relapsed/refractory AML. Key...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,388 to Histone Therapeutics, a woman-owned small business, aims to epigenetically modify natural killer (NK) cells to enhance their ability to detect and kill cancer cells. The goal is to develop a broad-spectrum NK cell therapy that can be used in combination with current cancer treatments to improve effectiveness without increasing side effects. The project will assess...